Participant flow

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy · Source last updated 2025-12-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received 40 milligrams (mg) cabozantinib oral tablets once daily + 1200 mg intravenous (IV) infusion of atezolizumab once every 3 weeks for up to 38 months.

   id

   FG000

   title

   Experimental Arm: Cabozantinib + Atezolizumab

2. description

   Participants received 60 mg cabozantinib oral tablets once daily for up to 38 months.

   id

   FG001

   title

   Single-Agent Cabozantinib

3. description

   Participants received 400 mg sorafenib oral tablets twice daily (BID) for up to 38 months.

   id

   FG002

   title

   Control Arm: Sorafenib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         10

      type

      Did not receive any study treatment

   2. reasons

      1. group Id

         FG000

         num Subjects

         204

      2. group Id

         FG001

         num Subjects

         92

      3. group Id

         FG002

         num Subjects

         115

      type

      Radiographic progression

   3. reasons

      1. group Id

         FG000

         num Subjects

         140

      2. group Id

         FG001

         num Subjects

         60

      3. group Id

         FG002

         num Subjects

         51

      type

      Adverse Event

   4. reasons

      1. group Id

         FG000

         num Subjects

         12

      2. group Id

         FG001

         num Subjects

         6

      3. group Id

         FG002

         num Subjects

         6

      type

      Lack of Efficacy

   5. reasons

      1. group Id

         FG000

         num Subjects

         26

      2. group Id

         FG001

         num Subjects

         23

      3. group Id

         FG002

         num Subjects

         24

      type

      Withdrawal by Subject

   6. reasons

      1. group Id

         FG000

         num Subjects

         41

      2. group Id

         FG001

         num Subjects

         5

      3. group Id

         FG002

         num Subjects

         7

      type

      Sponsor decision,

   7. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         2

      type

      Lost to Follow-up

   8. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         2

      type

      Protocol Violation

   9. reasons

      1. group Id

         FG000

         num Subjects

         5

      2. group Id

         FG001

         num Subjects

         2

      3. group Id

         FG002

         num Subjects

         0

      type

      Other than specified

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         432

      2. group Id

         FG001

         num Subjects

         188

      3. group Id

         FG002

         num Subjects

         217

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         429

      2. group Id

         FG001

         num Subjects

         188

      3. group Id

         FG002

         num Subjects

         207

      type

      Received At Least 1 Dose of Study Drug

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         432

      2. group Id

         FG001

         num Subjects

         188

      3. group Id

         FG002

         num Subjects

         217

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice